Nifty
:
20875.15
Sensex
:
69462.99
-62.55 (-0.30%)
-190.74 (-0.27%)
Nifty
Sensex
:
:
20875.15
69462.99
-62.55 (-0.30%)
-190.74 (-0.27%)

Lupin Ltd.

Pharmaceuticals & Drugs - Global

Rating :
59/99

BSE: 500257 | NSE: LUPIN

NSE BSE
1243.50
06-Dec-2023
  • Open
  • High
  • Low
  • Previous Close
  •  1258.20
  •  1266.90
  •  1238.65
  •  1258.20
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1449739
  •  18092.02
  •  1308.95
  •  628.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 56,617.40
  • 42.53
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 58,518.29
  • 0.32%
  • 4.28

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 47.06%
  • 0.41%
  • 6.24%
  • FII
  • DII
  • Others
  • 14.99%
  • 29.25%
  • 2.05%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.96
  • -0.13
  • 3.15

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -5.42
  • -8.41
  • -7.69

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -13.51
  • -6.80
  • -29.27

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.07
  • -
  • 26.03

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.57
  • 3.04
  • 3.20

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.75
  • 15.91
  • 17.20

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Net Sales
5,038.56
4,145.52
21.54%
4,814.06
3,743.84
28.59%
4,430.08
3,883.03
14.09%
4,322.22
4,160.93
3.88%
Expenses
4,120.80
3,692.53
11.60%
3,957.77
3,511.52
12.71%
3,852.31
3,615.21
6.56%
3,789.55
3,791.10
-0.04%
EBITDA
917.76
452.99
102.60%
856.29
232.32
268.58%
577.77
267.82
115.73%
532.67
369.83
44.03%
EBIDTM
18.21%
10.93%
17.79%
6.21%
13.04%
6.90%
12.32%
8.89%
Other Income
40.40
14.94
170.41%
22.83
5.56
310.61%
37.27
15.68
137.69%
17.96
34.06
-47.27%
Interest
80.64
54.88
46.94%
85.67
42.78
100.26%
92.55
41.47
123.17%
84.09
33.40
151.77%
Depreciation
247.85
203.47
21.81%
234.66
192.83
21.69%
263.99
327.19
-19.32%
220.40
203.43
8.34%
PBT
629.67
209.58
200.44%
558.79
2.27
24,516.30%
258.50
-85.16
-
246.14
167.06
47.34%
Tax
134.35
75.11
78.87%
105.46
89.09
18.37%
16.11
426.73
-96.22%
88.49
-382.00
-
PAT
495.32
134.47
268.35%
453.33
-86.82
-
242.39
-511.89
-
157.65
549.06
-71.29%
PATM
9.83%
3.24%
9.42%
-2.32%
5.47%
-13.18%
3.65%
13.20%
EPS
10.76
2.85
277.54%
9.94
-1.96
-
5.19
-11.40
-
3.37
12.01
-71.94%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
18,604.92
16,641.66
16,405.48
15,162.96
16,836.56
16,751.37
15,804.15
17,494.33
14,139.03
12,770.01
11,286.57
Net Sales Growth
16.77%
1.44%
8.19%
-9.94%
0.51%
5.99%
-9.66%
23.73%
10.72%
13.14%
 
Cost Of Goods Sold
6,800.71
6,023.89
5,780.84
4,854.28
4,962.72
4,436.67
4,733.76
4,660.97
3,893.70
3,806.16
3,485.50
Gross Profit
11,804.21
10,617.77
10,624.64
10,308.68
11,873.84
12,314.70
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
GP Margin
63.45%
63.80%
64.76%
67.99%
70.52%
73.51%
70.05%
73.36%
72.46%
70.19%
69.12%
Total Expenditure
15,720.43
14,921.09
16,190.24
12,596.08
14,362.21
14,082.44
12,656.64
13,001.19
10,453.68
9,150.42
8,283.78
Power & Fuel Cost
-
479.68
443.96
414.48
443.17
442.28
433.88
377.86
381.27
362.81
334.29
% Of Sales
-
2.88%
2.71%
2.73%
2.63%
2.64%
2.75%
2.16%
2.70%
2.84%
2.96%
Employee Cost
-
3,087.15
2,989.30
2,825.90
2,986.84
2,770.17
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
% Of Sales
-
18.55%
18.22%
18.64%
17.74%
16.54%
18.13%
16.29%
15.15%
13.68%
12.98%
Manufacturing Exp.
-
2,176.13
2,187.99
1,945.67
1,852.21
1,731.57
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
% Of Sales
-
13.08%
13.34%
12.83%
11.00%
10.34%
13.21%
12.98%
12.49%
10.34%
10.01%
General & Admin Exp.
-
1,733.07
3,490.62
1,218.42
1,456.46
3,302.60
1,219.96
1,509.56
1,195.98
806.87
810.53
% Of Sales
-
10.41%
21.28%
8.04%
8.65%
19.72%
7.72%
8.63%
8.46%
6.32%
7.18%
Selling & Distn. Exp.
-
1,188.72
1,096.10
1,026.40
1,080.45
1,206.60
1,150.61
1,049.48
870.29
835.48
775.26
% Of Sales
-
7.14%
6.68%
6.77%
6.42%
7.20%
7.28%
6.00%
6.16%
6.54%
6.87%
Miscellaneous Exp.
-
232.45
201.43
310.93
1,580.36
192.55
166.20
283.61
204.82
271.21
775.26
% Of Sales
-
1.40%
1.23%
2.05%
9.39%
1.15%
1.05%
1.62%
1.45%
2.12%
2.52%
EBITDA
2,884.49
1,720.57
215.24
2,566.88
2,474.35
2,668.93
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
EBITDA Margin
15.50%
10.34%
1.31%
16.93%
14.70%
15.93%
19.92%
25.68%
26.07%
28.34%
26.60%
Other Income
118.46
150.91
213.67
136.29
483.76
333.01
150.35
106.51
185.19
239.75
116.48
Interest
342.95
274.30
142.77
140.64
362.98
302.49
204.35
152.53
59.47
9.81
26.65
Depreciation
966.90
880.69
1,658.71
887.41
970.22
846.05
1,085.87
912.23
487.13
434.70
260.97
PBT
1,693.10
716.49
-1,372.57
1,675.12
1,624.91
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
Tax
344.41
268.80
137.15
448.52
1,146.56
901.69
288.46
978.51
1,059.34
970.40
962.15
Tax Rate
20.34%
37.52%
-9.99%
26.78%
131.36%
59.58%
53.10%
27.68%
31.87%
28.42%
33.98%
PAT
1,348.69
430.08
-1,528.04
1,215.20
-273.72
611.73
247.74
2,549.21
2,255.84
2,403.24
1,836.37
PAT before Minority Interest
1,331.36
447.69
-1,509.36
1,226.60
-273.72
611.73
254.83
2,556.38
2,264.60
2,444.43
1,869.50
Minority Interest
-17.33
-17.61
-18.68
-11.40
0.00
0.00
-7.09
-7.17
-8.76
-41.19
-33.13
PAT Margin
7.25%
2.58%
-9.31%
8.01%
-1.63%
3.65%
1.57%
14.57%
15.95%
18.82%
16.27%
PAT Growth
1,490.06%
-
-
-
-
146.92%
-90.28%
13.00%
-6.13%
30.87%
 
EPS
29.63
9.45
-33.57
26.70
-6.01
13.44
5.44
56.00
49.56
52.80
40.34

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
12,464.50
12,153.27
13,803.14
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
Share Capital
91.00
90.90
90.74
90.60
90.50
90.42
90.32
90.12
89.90
89.68
Total Reserves
12,224.56
11,900.64
13,522.87
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
Non-Current Liabilities
992.09
1,153.07
1,136.03
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
426.15
507.16
Secured Loans
0.00
141.86
0.33
0.70
358.82
448.03
217.15
5.55
12.50
24.42
Unsecured Loans
27.51
0.00
15.79
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
89.33
126.54
Long Term Provisions
343.03
332.99
329.49
296.29
370.79
356.85
308.73
190.00
162.03
132.49
Current Liabilities
9,265.37
8,276.44
8,436.09
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
Trade Payables
2,531.53
2,282.91
2,014.44
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
Other Current Liabilities
1,577.22
1,394.11
2,766.67
3,124.23
1,279.82
1,517.16
657.97
1,001.27
829.76
287.64
Short Term Borrowings
4,216.54
3,702.30
3,049.44
2,492.75
1,580.21
451.76
2,304.33
1,745.41
369.15
402.38
Short Term Provisions
940.08
897.12
605.54
1,195.92
771.66
551.23
569.39
325.67
574.26
345.40
Total Liabilities
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
Net Block
8,355.24
7,381.62
7,880.76
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
Gross Block
18,077.42
15,990.30
14,726.75
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
Accumulated Depreciation
9,698.33
8,608.68
6,845.99
6,222.39
4,645.17
3,497.87
1,362.37
495.11
2,276.40
1,928.30
Non Current Assets
10,348.98
9,193.81
9,443.86
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
Capital Work in Progress
1,237.99
1,146.28
1,066.26
939.62
1,639.71
2,598.20
2,133.06
2,702.40
551.87
285.90
Non Current Investment
77.13
77.60
78.07
36.07
185.63
26.71
22.00
14.33
2.51
2.06
Long Term Loans & Adv.
622.28
572.41
405.79
409.58
402.61
383.00
950.76
960.22
274.20
372.99
Other Non Current Assets
56.34
15.90
12.98
72.95
47.13
9.38
7.96
7.70
0.32
0.00
Current Assets
12,451.30
12,457.68
13,986.37
15,413.21
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
Current Investments
439.77
822.40
2,376.81
2,338.25
2,109.86
234.86
2,114.13
2.02
1,655.89
176.41
Inventories
4,491.76
4,630.73
4,092.01
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
Sundry Debtors
4,480.70
4,261.94
4,474.32
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
Cash & Bank
1,293.13
1,098.13
1,742.46
2,454.30
987.20
1,408.03
698.17
821.75
481.35
797.50
Other Current Assets
1,745.94
497.54
556.89
537.33
1,769.95
1,711.95
1,191.01
1,241.22
534.98
532.99
Short Term Loans & Adv.
1,077.50
1,146.94
743.88
1,180.53
992.48
1,090.65
657.58
761.78
294.91
275.15
Net Current Assets
3,185.93
4,181.24
5,550.28
6,188.01
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
Total Assets
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
1,897.24
367.31
1,821.76
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
PBT
716.49
-1,372.21
1,676.45
876.78
1,517.17
546.81
3,543.14
3,328.84
3,414.83
2,831.65
Adjustment
1,097.41
1,707.68
1,033.16
1,574.29
1,588.41
2,782.23
1,214.74
585.35
356.73
410.50
Changes in Working Capital
326.52
-15.04
-192.49
-471.02
-500.19
-1,019.43
504.62
-3,126.44
-94.91
-466.31
Cash after chg. in Working capital
2,140.42
320.43
2,517.12
1,980.05
2,605.39
2,309.61
5,262.50
787.75
3,676.65
2,775.84
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-243.18
46.88
-695.36
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,286.77
1,292.23
-1,239.58
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
-858.54
Net Fixed Assets
-682.44
-471.44
-693.00
-481.49
-462.56
-1,394.31
-876.24
480.96
-416.45
-309.36
Net Investments
-463.24
51.49
-2,106.15
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
Others
-141.09
1,712.18
1,559.57
1,656.44
-794.29
313.11
1,521.90
-7,146.08
1,642.51
-73.56
Cash from Financing Activity
-337.25
-1,572.32
-1,885.27
-890.58
744.13
-1,492.10
433.18
5,836.38
-196.89
-857.11
Net Cash Inflow / Outflow
273.22
87.22
-1,303.09
1,685.25
-872.37
728.96
2,019.25
-1,507.72
1,481.65
288.28
Opening Cash & Equivalents
991.37
926.22
2,229.31
544.06
1,416.43
687.47
780.22
2,095.06
606.62
310.93
Closing Cash & Equivalent
1,264.59
1,013.44
926.22
2,229.31
544.06
1,416.43
2,799.47
780.22
2,108.43
606.62

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
270.67
263.84
300.06
272.01
298.87
295.64
295.04
245.21
196.17
154.00
ROA
2.01%
-6.70%
5.09%
-1.05%
2.32%
0.99%
10.57%
12.82%
21.08%
19.70%
ROE
3.68%
-11.79%
9.46%
-2.12%
4.55%
1.91%
20.98%
22.80%
31.09%
30.89%
ROCE
6.06%
-7.11%
9.70%
6.02%
8.45%
3.54%
18.53%
24.38%
40.30%
40.97%
Fixed Asset Turnover
1.67
1.93
1.96
2.10
1.93
2.07
1.63
1.80
2.16
2.28
Receivable days
56.09
53.73
64.06
61.62
66.11
63.76
91.82
92.24
72.65
74.67
Inventory Days
58.53
53.64
48.75
42.41
47.94
49.03
71.70
73.96
65.73
65.48
Payable days
141.88
132.55
161.68
65.89
68.49
68.56
60.60
63.20
64.43
63.78
Cash Conversion Cycle
-27.27
-25.18
-48.88
38.14
45.56
44.23
102.92
103.00
73.94
76.37
Total Debt/Equity
0.34
0.32
0.35
0.51
0.63
0.53
0.60
0.65
0.06
0.09
Interest Cover
3.61
-8.61
12.91
3.40
6.00
3.66
24.18
56.89
349.10
107.25

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Lupin receives approval from USFDA for Varenicline Tablets
    6th Dec 2023, 09:58 AM

    The product will be manufactured at Lupin’s Pithampur facility in India

    Read More
  • Lupin launches Turqoz tablets in United States
    1st Dec 2023, 17:11 PM

    Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of $33 million in the U.S

    Read More
  • Lupin gets USFDA’s tentative nod for Canagliflozin Tablets
    23rd Nov 2023, 16:22 PM

    This product will be manufactured at Lupin’s Pithampur facility in India

    Read More
  • Lupin gets USFDA’s approval for Bromfenac Ophthalmic Solution
    23rd Nov 2023, 16:08 PM

    The product will be manufactured at Lupin’s Pithampur facility in India

    Read More
  • Lupin launches world’s first fixed-dose triple combination drug ‘Vilfuro-G’
    23rd Nov 2023, 11:42 AM

    Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide, for the long-term management and treatment of moderate to severe COPD

    Read More
  • Lupin gets USFDA’s approval for Pitavastatin Tablets
    21st Nov 2023, 16:30 PM

    The product will be manufactured at Lupin’s Pithampur facility in India

    Read More
  • Lupin gets tentative nod for Dapagliflozin Tablets from USFDA
    21st Nov 2023, 16:22 PM

    This product will be manufactured at Lupin’s Pithampur facility in India

    Read More
  • Lupin receives USFDA’s approval for Ganirelix Acetate Injection
    17th Nov 2023, 15:14 PM

    The product will be manufactured at Lupin’s Nagpur facility in India

    Read More
  • Lupin partners with Amman Pharmaceuticals Industries
    10th Nov 2023, 12:17 PM

    Both Lupin and Amman Pharma are united in their mission to provide innovative, high-quality healthcare solutions to patients in the MENA region

    Read More
  • Lupin reports over 3-fold jump in Q2 consolidated net profit
    9th Nov 2023, 11:17 AM

    Total consolidated income of the company increased by 22.08% at Rs 5,078.96 crore for Q2FY24

    Read More
  • Lupin - Quarterly Results
    8th Nov 2023, 22:56 PM

    Read More
  • Lupin launches Rocuronium Bromide Injection in United States
    8th Nov 2023, 12:11 PM

    Rocuronium Bromide Injection had estimated annual sales of $54 million in the U.S.

    Read More
  • Lupin gets USFDA’s tentative nod for Canagliflozin, Metformin Hydrochloride Extended-Release Tablets
    7th Nov 2023, 18:26 PM

    This product will be manufactured at Lupin’s Pithampur facility in India

    Read More
  • Lupin inks licensing agreement with Zydus Lifesciences
    3rd Nov 2023, 16:20 PM

    The company will have semi-exclusive rights to co-market the product in India under the brand name LINVAS

    Read More
  • Lupin launches Diazepam Rectal Gel in United States
    2nd Nov 2023, 18:03 PM

    Diazepam Rectal Gel (RLD Diastat AcuDial) had estimated annual sales of $37 million in the U.S.

    Read More
  • Lupin receives USFDA’s approval for Selexipag for Injection
    2nd Nov 2023, 12:59 PM

    This product will be manufactured at Lupin’s Nagpur facility in India

    Read More
  • Lupin gets EIR from USFDA for Mandideep Unit-2 manufacturing facility
    1st Nov 2023, 10:41 AM

    The inspection closed with the facility receiving an inspection classification of ‘No Action Indicated’

    Read More
  • Lupin gets USFDA’s nod for Fluconazole Tablets
    23rd Oct 2023, 16:24 PM

    This product will be manufactured at Lupin’s Pithampur facility in India

    Read More
  • Lupin inks BTA to carve out two API manufacturing sites
    17th Oct 2023, 16:00 PM

    Earlier, the company had received approval from board of directors to enter into a business transfer agreement

    Read More
  • Lupin gets USFDA’s tentative nod for Apalutamide Tablets
    13th Oct 2023, 15:47 PM

    This product will be manufactured at Lupin’s Pithampur facility in India

    Read More
  • Lupin gets tentative approval for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution
    13th Oct 2023, 09:30 AM

    This product will be manufactured at Lupin’s Somerset facility in the US

    Read More
  • Lupin gets USFDA’s tentative nod for Tolvaptan Tablets
    5th Oct 2023, 17:35 PM

    This product will be manufactured at Lupin’s Nagpur facility in India

    Read More
  • Lupin launches ‘Humrahi’ unique patient support program for diabetes management
    3rd Oct 2023, 15:48 PM

    Humrahi, translating to ‘Companion’ is a guide in the journey of diabetes management

    Read More
  • Lupin receives EIR from USFDA for Nagpur Unit-1 manufacturing facility
    29th Sep 2023, 16:00 PM

    The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated

    Read More
  • Lupin’s Joint Airways Initiative surpasses 10,000 patients
    28th Sep 2023, 14:29 PM

    JAI, a visionary initiative by Lupin, equips patients with the knowledge and skills to manage their condition effectively

    Read More
  • Lupin inks pact to acquire five legacy brands from Menarini
    22nd Sep 2023, 14:30 PM

    This strategic acquisition for the Indian market marks a significant step forward for Lupin as it continues to expand its presence in India

    Read More
  • Lupin gets nod to enter into business transfer agreement with LMSL
    12th Sep 2023, 09:40 AM

    The Board of Directors at its meeting held on September 11, 2023 has approved the same

    Read More
  • Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD Foundation
    6th Sep 2023, 18:16 PM

    This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US

    Read More
  • Lupin’s arm launches Propranolol LA capsules
    30th Aug 2023, 09:31 AM

    This extended-release variant not only ensures consistent alleviation of symptoms but also enhances patient adherence and overall quality of life

    Read More
  • Lupin gets USFDA’s nod for Pirfenidone Capsules
    29th Aug 2023, 14:22 PM

    This product will be manufactured at Lupin’s Pithampur facility in India

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.